Alto Neuroscience(US:ANRO) Businesswire·2026-02-23 13:33Company Overview - Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing novel precision medicines for neuropsychiatric disorders [1] - The company aims to redefine psychiatry by leveraging neurobiology to create personalized and effective treatment options [1] Upcoming Investor Conferences - Alto Neuroscience will participate in the TD Cowen 46th Annual Healthcare Conference from March 2-5, 2026, with a presentation scheduled for March 3, 2026, at 1:50 pm EST [1] - The company will also attend the Jefferies 2026 Biotech on the Beach Summit on March 10-11, 2026, focusing on one-on-one investor meetings [1] - Presentations will be accessible via a live webcast on Alto's investor relations website, with replays available afterward [1] Clinical Development - Alto Neuroscience has completed patient enrollment in its Phase 2 proof-of-concept clinical trial for ALTO-101, a transdermal phosphodiesterase-4 (PDE4) inhibitor targeting cognitive impairment associated with schizophrenia [1] - The company’s clinical-stage pipeline includes novel drug candidates for depression, schizophrenia, and other mental health conditions [1] Intellectual Property - Alto Neuroscience has strengthened its intellectual property portfolio with the issuance of U.S. Patent Number 12,521,374, which covers methods of treating depression with ALTO-207, a combination of pramipexole and ondansetron [1] - This patent protects the use of ondansetron to mitigate side effects related to pramipexole in the treatment of depression [1]